Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.49 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 11/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 11/20 | 0.44 |
| ▸ | CDK1 | P06493 | 8/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.44 |
| ▸ | CDK2 | P24941 | 7/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 2/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534889 | 0.88 | GSK3B (1.00) | GSK3BFGFR1FGFR2FGFR3KDR | |
| SCHEMBL3423433 | 0.82 | GSK3B (0.61) | GSK3BCHEK1MAPK8 | |
| SCHEMBL3423290 | 0.77 | GSK3B (0.63) | GSK3BCHEK1 | |
| SCHEMBL3533605 | 0.76 | GSK3B (0.77) | GSK3BFGFR1FGFR2FGFR3KDR | |
| SCHEMBL3539736 | 0.76 | GSK3B (0.77) | GSK3BFGFR1FGFR2FGFR3KDR | |
| SCHEMBL2950639 | 0.76 | GSK3B (0.66) | GSK3BHDAC6 | |
| SCHEMBL3541775 | 0.76 | GSK3B (0.77) | GSK3BFGFR1FGFR2FGFR3KDR | |
| SCHEMBL30434521 | 0.75 | GSK3B (0.51) | GSK3BHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL148677 | 0.75 | GSK3B (0.51) | GSK3BHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL3537777 | 0.75 | GSK3B (0.76) | GSK3BFGFR1FGFR2FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | claimed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| EP-1725543-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085230-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | GSK3B, GSK3A, PYGB | GSK3B 1/4885FGFR1 1854/4885FGFR2 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.